New hope for myelofibrosis patients: tasquinimod trial launches
NCT ID NCT06327100
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a drug called tasquinimod, either alone or with the standard drug ruxolitinib, in 33 people with myelofibrosis (a type of bone marrow cancer). The goal is to see if the combination is safe and can help control the disease, especially in patients who have not responded to other treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tasquinimod (given alone or with ruxolitinib)
- What this could lead to
- If it works, this could offer a new treatment option for people with myelofibrosis who have not responded to or cannot take standard therapies.
- What could go wrong
- This is an early-phase trial with only 33 participants, so results may not apply widely. The drug may cause side effects or fail to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST POLYCYTHEMIA VERA MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Action pill tame bone marrow tumors?
- Can a new pill shrink the spleen in myelofibrosis?
- Can a daily pill shrink the spleen in myelofibrosis?
- Could a platelet-boosting drug shorten recovery after stem cell transplants?
- Can a new pill tame myelofibrosis?
- Can a menin inhibitor tame myelofibrosis when standard drugs fall short?